Table 1.

ongoing studies for locally advanced cervical cancer.

Trial	Phase	Treatment regimens	Primary end-point
NCT04580771	II	CRT + vaccine PDS0101 SC on days -10, 7, 28, 49, and 170	Safety and toxicity
NCT05504642	II	Induction IT (Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV two weeks before CRT) followed by concurrent CRT and IT (Nivolumab 3mg/kg week 1, 3, 5, 7 and Ipilimumab 1mg/kg in week 5) followed by IT maintenance (Nivolumab 3mg/kg every two weeks x12 and Ipilimumab every six weeks x4)	PFS
NCT05173272	III	Neoadjuvant chemotherapy (Cisplatin 50 mg/m^2 d1 q21+ Paclitaxel 175 mg/m^2 d1 q21) combined with serplulimab (300mg d1 q21) followed by CRT and BT vs CRT + BT	PFS
NCT02635360	II	CRT + BT followed by IT (200 mg of pembrolizumab every 21 days for 3 months) or CRT + BT with concurrent IT (200 mg of pembrolizumab every 21 days for 3 months)	Change in immunologic markers following combination of study drug with CRT and Incidence of dose limiting toxicities
NCT03833479	II	CRT + BT vs CRT + BT followed by maintenance IT (Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months)	PFS
NCT05492123	II	CRT + BT vs induction nivolumab (1mg/kg every 3 weeks for 4 cycles)-ipilimumab (3mg/kg every 3 weeks for 4 cycles), followed by nivolumab (240mg every 2 weeks) with CRT and BT	3-year PFS
NCT03612791	II	CRT + BT vs atezolizumab (1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles) with CRT and BT	PFS
NCT05311566	II	CRT + BT vs Camrelizumab (200mg, every 2 weeks and continued as an adjuvant) with CRT and BT	3-year OS rate
NCT04221945	III	CRT + BT vs pembrolizumab (200 mg on Day 1 of each 3-week cycle for 5 cycles during CRT followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles.) with CRT and BT	PFS OS

CRT, chemoradiation therapy; BT, brachytherapy; IT, immunotherapy; PFS, progression-free survival; OS, overall survival.